Zanita Kassam, MD
Obstetrics & Gynecology · Rancho Mirage, CANPI 1225340243
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,352 of the $1,634 with a category attached, or 82.8%. 4 manufacturers reported payments, led by Coloplast at 36.7% of the total. Reporting peaked in 2024 at $781 and has fallen 96.8% since, to $25 in 2025.
Across 33 payments — averaging $49.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$600
- AbbVie$560
- Hologic Sales And Service, LLC$388
- Coopersurgical, Inc.$85
Across 5 payments — averaging $7913.96 each. An ownership or investment interest held by the physician or an immediate family member.
- Catalyst Orthoscience$40K
What the payments were for
- Travel & lodging$28217%
- Food & beverage$1,35283%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 5 | $600 |
| AbbVie | 22 | $560 |
| Hologic Sales And Service, LLC | 5 | $388 |
| Coopersurgical, Inc. | 1 | $85 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,634 in reported general payments places this provider in the 70th percentile of 3,784 obstetrics & gynecology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 132 | $8,137 |
| VeozahFezolinetant | 12 | $6,284 |
| Clobetasol Propionate | 41 | $2,940 |
| Estradiol (Twice Weekly)Estradiol | 41 | $2,544 |
| Estradiol (Once Weekly)Estradiol | 12 | $1,209 |
| ProgesteroneProgesterone, Micronized | 18 | $976 |
| ValacyclovirValacyclovir Hcl | 13 | $325 |
| Fluconazole | 15 | $138 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $132 |
| Misoprostol | 38 | $88 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Rancho Mirage
- Steve YuNorthridge$964K
- Samir HageRedlands$640K
- Malcolm MunroLos Angeles$609K
- Michael KrychmanCosta Mesa$547K
- Anita NelsonTorrance$530K
- Jan SegnitzSan Jose$511K
- Risa KaganBerkeley$497K
- Michael GreenOxnard$424K
- Howard SalvaySanta Cruz$421K
- Marc WinterLaguna Hills$399K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.